Kerala High Court: ED Can Investigate Without FIR in Scheduled Offence Cases (CMRL Matter)  ||  Delhi High Court Upholds TRAI Rule Capping TV Advertisements at 12 Minutes Per Hour  ||  Supreme Court Directs High Courts to Deliver Judgments in 3 Months and Bail Orders in One Day  ||  Supreme Court: Successful Resolution Applicant Cannot Negotiate Further After CoC Approval  ||  Supreme Court: Succession Law Applies, Not Primogeniture, to Ex-Royal’s Private Estate Inheritance  ||  Supreme Court: Writ Jurisdiction Cannot Challenge Arbitrator’s Section 16 Decision  ||  Supreme Court: Sanyasi Status Cannot Be Ground to Reject Land Compensation Claim  ||  Supreme Court: Section 33(1)(a) of Arbitration Act Cannot Alter Nature of Interest in Award  ||  Supreme Court: Society Office Bearers Not Liable for Cheque Dishonour Without Active Business Role  ||  Supreme Court: Asking a Woman to Adjust in Marriage Does Not Amount to Cruelty By In-Laws    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved